{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:02:15Z","timestamp":1772269335747,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T00:00:00Z","timestamp":1343174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T00:00:00Z","timestamp":1343174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s10637-012-9855-1","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T04:37:44Z","timestamp":1343104664000},"page":"293-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line"],"prefix":"10.1007","volume":"31","author":[{"given":"Roudy Chiminch","family":"Ekyalongo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,25]]},"reference":[{"key":"9855_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"9855_CR2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497\u20131500","journal-title":"Science"},{"key":"9855_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139","journal-title":"N Engl J Med"},{"key":"9855_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472\u2013480","journal-title":"N Engl J Med"},{"key":"9855_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786\u2013792","journal-title":"N Engl J Med"},{"key":"9855_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.gastro.2004.02.021","volume":"127","author":"E Tamborini","year":"2004","unstructured":"Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294\u2013299","journal-title":"Gastroenterology"},{"key":"9855_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039\u20131043","journal-title":"Science"},{"key":"9855_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc1387","volume":"4","author":"MN Pollak","year":"2004","unstructured":"Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505\u2013518","journal-title":"Nat Rev Cancer"},{"key":"9855_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1365-2141.2008.07049.x","volume":"141","author":"P Maiso","year":"2008","unstructured":"Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, Garcia-Echeverria C, Zimmermann J, Pandiella A, San Miguel JF (2008) The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 141:470\u2013482","journal-title":"Br J Haematol"},{"key":"9855_CR10","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1158\/0008-5472.CAN-04-3192","volume":"65","author":"K Scotlandi","year":"2005","unstructured":"Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, Garcia-Echeverria C, Hofmann F, Picci P (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65:3868\u20133876","journal-title":"Cancer Res"},{"key":"9855_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10911-008-9107-3","volume":"13","author":"Q Jin","year":"2008","unstructured":"Jin Q, Esteva FJ (2008) Cross-talk between the ErbB\/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485\u2013498","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"9855_CR12","doi-asserted-by":"crossref","unstructured":"Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 70:1204\u20131214","DOI":"10.1158\/0008-5472.CAN-09-3321"},{"key":"9855_CR13","doi-asserted-by":"crossref","first-page":"944s","DOI":"10.1158\/1078-0432.944s.11.2","volume":"11","author":"YH Ibrahim","year":"2005","unstructured":"Ibrahim YH, Yee D (2005) Insulin-like growth factor-I and breast cancer therapy. Clin Cancer Res 11:944s\u2013950s","journal-title":"Clin Cancer Res"},{"key":"9855_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.humpath.2004.09.005","volume":"35","author":"C Shimizu","year":"2004","unstructured":"Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N, Fujiwara Y (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35:1537\u20131542","journal-title":"Hum Pathol"},{"key":"9855_CR15","first-page":"6035","volume":"62","author":"Q Chang","year":"2002","unstructured":"Chang Q, Li Y, White MF, Fletcher JA, Xiao S (2002) Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 62:6035\u20136038","journal-title":"Cancer Res"},{"key":"9855_CR16","first-page":"103","volume":"3","author":"RL Rocha","year":"1997","unstructured":"Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV, Yee D (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3:103\u2013109","journal-title":"Clin Cancer Res"},{"key":"9855_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2009.02.056","volume":"282","author":"T Mukohara","year":"2009","unstructured":"Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, Janne PA, Saijo N, Minami H (2009) Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett 282:14\u201324","journal-title":"Cancer Lett"},{"key":"9855_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627\u2013644","journal-title":"Nat Rev Drug Discov"},{"key":"9855_CR19","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Y Lu","year":"2001","unstructured":"Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852\u20131857","journal-title":"J Natl Cancer Inst"},{"key":"9855_CR20","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","volume":"69","author":"L Liu","year":"2009","unstructured":"Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM (2009) Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69:6871\u20136878","journal-title":"Cancer Res"},{"key":"9855_CR21","doi-asserted-by":"publisher","first-page":"26904","DOI":"10.1074\/jbc.M605371200","volume":"281","author":"EW Arvisais","year":"2006","unstructured":"Arvisais EW, Romanelli A, Hou X, Davis JS (2006) AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2alpha. J Biol Chem 281:26904\u201326913","journal-title":"J Biol Chem"},{"key":"9855_CR22","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1074\/jbc.M103808200","volume":"277","author":"A Gonzalez-Garcia","year":"2002","unstructured":"Gonzalez-Garcia A, Garrido E, Hernandez C, Alvarez B, Jimenez C, Cantrell DA, Pullen N, Carrera AC (2002) A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 kinase activation. J Biol Chem 277:1500\u20131508","journal-title":"J Biol Chem"},{"key":"9855_CR23","doi-asserted-by":"crossref","unstructured":"Markova B, Albers C, Breitenbuecher F, Melo JV, Brummendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR\/p70S6-kinase pathway. Oncogene 29:739\u2013751","DOI":"10.1038\/onc.2009.374"},{"key":"9855_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550\u2013562","journal-title":"Nat Rev Cancer"},{"key":"9855_CR25","doi-asserted-by":"crossref","unstructured":"Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21:255\u2013262","DOI":"10.1093\/annonc\/mdp304"},{"key":"9855_CR26","doi-asserted-by":"crossref","unstructured":"Nahta R, O\u2019Regan RM. Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K\/Akt\/mTOR Pathway. Clin Breast Cancer 10:S72\u201378","DOI":"10.3816\/CBC.2010.s.015"},{"key":"9855_CR27","doi-asserted-by":"crossref","unstructured":"Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS. GAS6\/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12:116\u2013127","DOI":"10.1593\/neo.91384"},{"key":"9855_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1471-4159.2008.05343.x","volume":"106","author":"JG Weinger","year":"2008","unstructured":"Weinger JG, Gohari P, Yan Y, Backer JM, Varnum B, Shafit-Zagardo B (2008) In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; in vitro mutagenesis defines the requisite binding sites for downstream Akt activation. J Neurochem 106:134\u2013146","journal-title":"J Neurochem"},{"key":"9855_CR29","doi-asserted-by":"crossref","unstructured":"Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 107:1124\u20131129","DOI":"10.1073\/pnas.0909333107"},{"key":"9855_CR30","doi-asserted-by":"crossref","unstructured":"Li-Ping Z, Da-Lei Z, Jian H, Liang-Quan X, Ai-Xia X, Xiao-Yu D, Dan-Feng T, Yue-Hui Z. Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways. Reprod Biol Endocrinol 8:66","DOI":"10.1186\/1477-7827-8-66"},{"key":"9855_CR31","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.4049\/jimmunol.0804384","volume":"183","author":"S Scutera","year":"2009","unstructured":"Scutera S, Fraone T, Musso T, Cappello P, Rossi S, Pierobon D, Orinska Z, Paus R, Bulfone-Paus S, Giovarelli M (2009) Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl\/Gas6 pathway. J Immunol 183:3004\u20133013","journal-title":"J Immunol"},{"key":"9855_CR32","first-page":"5016","volume":"11","author":"JP O\u2019Bryan","year":"1991","unstructured":"O\u2019Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau MM, Earp HS, Liu ET (1991) axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11:5016\u20135031","journal-title":"Mol Cell Biol"},{"key":"9855_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2008.04.017","volume":"268","author":"CC Hong","year":"2008","unstructured":"Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE (2008) Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268:314\u2013324","journal-title":"Cancer Lett"},{"key":"9855_CR34","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1038\/onc.2009.212","volume":"28","author":"Y Li","year":"2009","unstructured":"Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ, Pei L (2009) Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28:3442\u20133455","journal-title":"Oncogene"},{"key":"9855_CR35","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1158\/0008-5472.CAN-06-3191","volume":"67","author":"JD Lay","year":"2007","unstructured":"Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE (2007) Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67:3878\u20133887","journal-title":"Cancer Res"},{"key":"9855_CR36","doi-asserted-by":"publisher","first-page":"17025","DOI":"10.1073\/pnas.0909292106","volume":"106","author":"S Zhu","year":"2009","unstructured":"Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, Walker J, Sun F, Orth A, Schultz PG, Wu X (2009) A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A 106:17025\u201317030","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9855_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/molehr\/gag082","volume":"9","author":"WS Sun","year":"2003","unstructured":"Sun WS, Fujimoto J, Tamaya T (2003) Clinical implications of coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine leiomyoma. Mol Hum Reprod 9:701\u2013707","journal-title":"Mol Hum Reprod"},{"key":"9855_CR38","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/annonc\/mdg257","volume":"14","author":"WS Sun","year":"2003","unstructured":"Sun WS, Fujimoto J, Tamaya T (2003) Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Ann Oncol 14:898\u2013906","journal-title":"Ann Oncol"},{"key":"9855_CR39","doi-asserted-by":"crossref","unstructured":"Hagerstrand D, Lindh MB, Pena C, Garcia-Echeverria C, Nister M, Hofmann F, Ostman A. PI3K\/PTEN\/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro Oncol 12:967\u2013975","DOI":"10.1093\/neuonc\/noq029"},{"key":"9855_CR40","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/ijc.22126","volume":"119","author":"AS Guerreiro","year":"2006","unstructured":"Guerreiro AS, Boller D, Shalaby T, Grotzer MA, Arcaro A (2006) Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int J Cancer 119:2527\u20132538","journal-title":"Int J Cancer"},{"key":"9855_CR41","unstructured":"Attias-Geva Z, Bentov I, Fishman A, Werner H, Bruchim. I Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol Oncol"},{"key":"9855_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10911-008-9104-6","volume":"13","author":"SJ Weroha","year":"2008","unstructured":"Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials\u2013early lessons. J Mammary Gland Biol Neoplasia 13:471\u2013483","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"9855_CR43","doi-asserted-by":"publisher","first-page":"12565","DOI":"10.1074\/jbc.275.17.12565","volume":"275","author":"CA Molloy","year":"2000","unstructured":"Molloy CA, May FE, Westley BR (2000) Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 275:12565\u201312571","journal-title":"J Biol Chem"},{"key":"9855_CR44","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1677\/joe.1.07016","volume":"191","author":"S Maor","year":"2006","unstructured":"Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, Papa MZ (2006) Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 191:605\u2013612","journal-title":"J Endocrinol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-012-9855-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9855-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:42:18Z","timestamp":1678560138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9855-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,25]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["9855"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9855-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,25]]},"assertion":[{"value":"15 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}